Literature DB >> 29800569

Effect of long non-coding RNA H19 on oxidative stress and chemotherapy resistance of CD133+ cancer stem cells via the MAPK/ERK signaling pathway in hepatocellular carcinoma.

Kai Ding1, Yannian Liao1, Dinghao Gong1, Xin Zhao1, Wu Ji2.   

Abstract

We explored the ability of a long non-coding RNA H19, to influence oxidative stress (OS) and chemotherapy resistance of CD133 + cancer stem cells via the MAPK/ERK signaling pathway in HCC. HCC tissues with corresponding adjacent normal tissues were collected. CD133 + HuH7 cells were sorted and assigned into five groups. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were performed to determine expression levels mRNAs and proteins. Levels of reactive oxygen species (ROS) and malonaldehyde (MDA), and activity of superoxide dismutase (SOD) were measured. Cell viability was analyzed by MTT assay and cell apoptosis by flow cytometry. Compared with adjacent normal tissues, the H19 expression level was higher and MAPK and ERK protein levels were lower in HCC tissues. Compared with the blank group, in the pcDNA-H19 group, H19 expression level, MAPK and ERK protein levels, MDR1 and GST-π expression levels were increased, ROS and MDA levels were decreased, SOD activity was weakened, cell viability was promoted, and cell apoptosis was inhibited; in the siH19 group, H19 expression level, MAPK and ERK protein levels, MDR1 and GST-π expression levels were reduced, ROS and MDA levels were elevated, SOD activity was enhanced, cell viability was inhibited, and cell apoptosis was promoted. There was no significant difference among blank, NC and pcDNA-H19 + PD98059 groups. The study provides evidence that downregulation of H19 may induce OS and reverse chemotherapy resistance of CD133 + cancer stem cells by blocking the MAPK/ERK signaling pathway in HCC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CD133+; Cancer stem cells; H19; Hepatocellular carcinoma; MAPK/ERK signaling pathway

Mesh:

Substances:

Year:  2018        PMID: 29800569     DOI: 10.1016/j.bbrc.2018.05.143

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  24 in total

1.  lncRNA ST3GAL6‑AS1 promotes invasion by inhibiting hnRNPA2B1‑mediated ST3GAL6 expression in multiple myeloma.

Authors:  Ying Shen; Yuandong Feng; Fangmei Li; Yachun Jia; Yue Peng; Wanhong Zhao; Jinsong Hu; Aili He
Journal:  Int J Oncol       Date:  2021-03-02       Impact factor: 5.650

2.  Long non-coding RNA exploration for mesenchymal stem cell characterisation.

Authors:  Sébastien Riquier; Marc Mathieu; Chloé Bessiere; Anthony Boureux; Florence Ruffle; Jean-Marc Lemaitre; Farida Djouad; Nicolas Gilbert; Thérèse Commes
Journal:  BMC Genomics       Date:  2021-06-04       Impact factor: 3.969

Review 3.  Long noncoding RNA H19 - a new player in the pathogenesis of liver diseases.

Authors:  Zhihong Yang; Ting Zhang; Sen Han; Praveen Kusumanchi; Nazmul Huda; Yanchao Jiang; Suthat Liangpunsakul
Journal:  Transl Res       Date:  2020-11-20       Impact factor: 10.171

Review 4.  Crosstalk between noncoding RNAs and ferroptosis: new dawn for overcoming cancer progression.

Authors:  Lei Zhang; Xiulan Zheng; Wen Cheng; Xuefei Zhang; Lingling Wang; Haixia Li
Journal:  Cell Death Dis       Date:  2020-07-24       Impact factor: 8.469

5.  Long Noncoding RNA H19 Facilitates Small Cell Lung Cancer Tumorigenesis Through miR-140-5p/FGF9 Axis.

Authors:  Xingkai Li; Fang Lv; Fang Li; Minjun Du; Yicheng Liang; Shaolong Ju; Zixu Liu; Bing Wang; Yushun Gao
Journal:  Onco Targets Ther       Date:  2020-04-28       Impact factor: 4.147

Review 6.  The Underlying Mechanisms of Noncoding RNAs in the Chemoresistance of Hepatocellular Carcinoma.

Authors:  Man Wang; Fei Yu; Xinzhe Chen; Peifeng Li; Kun Wang
Journal:  Mol Ther Nucleic Acids       Date:  2020-05-15       Impact factor: 8.886

7.  Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.

Authors:  Yifei Dai; Weijie Qiang; Xiankuo Yu; Siwei Cai; Kequan Lin; Lan Xie; Xun Lan; Dong Wang
Journal:  Comput Struct Biotechnol J       Date:  2020-05-18       Impact factor: 7.271

8.  Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway.

Authors:  Junfeng Ye; Di Sun; Ying Yu; Jinhai Yu
Journal:  Aging (Albany NY)       Date:  2020-07-16       Impact factor: 5.682

9.  Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11.

Authors:  Zhicheng Yao; Ruiyun Xu; Lin Yuan; Mingxing Xu; Haiyun Zhuang; Yanjie Li; Yi Zhang; Nan Lin
Journal:  Cell Death Dis       Date:  2019-12-10       Impact factor: 8.469

10.  Galangin promotes cell apoptosis through suppression of H19 expression in hepatocellular carcinoma cells.

Authors:  Xiaowei Zhong; Siyi Huang; Dianfeng Liu; Ziping Jiang; Qinglong Jin; Chengshun Li; Liu Da; Qunyan Yao; Dongxu Wang
Journal:  Cancer Med       Date:  2020-06-02       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.